ADAMA Reports Fourth Quarter and Full Year 2025 Results

Improvements in key financial metrics reflect success of business transformation plan

BEIJING and TEL AVIV, Israel, March 27, 2026 /PRNewswire/ -- ADAMA Ltd. (the "Company") (SZSE: 000553), today reported its financial results for the fourth quarter and full year ended December 31, 2025.

Fourth Quarter 2025 Highlights:

• Sales declined 8% (-9% in RMB) to $1,026 million, mainly reflecting decreases of 8% in volumes and 2% in prices
• Adjusted gross profit up 12% to $314 million, with an improvement in gross margin from 25.2% in Q4 2024 to 30.6% in Q4 2025, reflecting the benefits of lower costs
• Adjusted EBITDA up 14% to $157 million, with an improvement of EBITDA margin from 12.3% in Q4 2024 to 15.3% in Q4 2025
• Reported net loss declined by $61 million to $88 million, compared to $149 million in Q4 2024; Adjusted net loss reduced to $1 million from $58 million in Q4 2024;
• Improvement of $111 million in operating cash flow, reaching $237 million in Q4 2025 vs. $126 million in Q4 2024
• Improvement of $118 million in free cash flow, reaching $156 million in Q4 2025 vs. $38 million in Q4 2024

Full Year 2025 Highlights:

• Sales declined 2% (-2% in RMB) to $4,051 million, reflecting 2% decrease in prices and stable volumes
• Adjusted gross profit up 12% to $1,192 million, with an improvement in gross margin from 25.6% in 2024 to 29.4% in the full year of 2025, reflecting the benefits of lower costs
• Adjusted EBITDA up 25% to $587 million, with an improvement in EBITDA margin from 11.3% in 2024 to 14.5% in the full year of 2025
• Reported net loss declined by $260 million to $147 million, compared to $407 million in 2024; Adjusted net income turned positive to $28 million from a loss of $206 million in 2024;
• Improvement of $39 million in operating cash flow, reaching $567 million in the full year vs. $528 million in 2024
• Improvement of $51 million in free cash flow, reaching $269 million in the full year vs. $217 million in 2024

Gaël Hili, President and CEO of ADAMA, said, "ADAMA's 2025 financial results show important improvements in key financial metrics including continued growth in EBITDA and its margin; increased cash generation; significantly reduced reported net loss; and an adjusted net profit. These encouraging successes reflect the strong foundation we have built over the past two years through our Fight Forward transformation plan, where we focused on  improving cost competitiveness, enhancing our commercial capabilities, and advancing our innovation portfolio and pipeline."

"This foundation is now a healthy base on which to build profitable growth. ADAMA is committed to maintaining the discipline and continuous improvement mindset that we built through Fight Forward. I am confident that ADAMA's continued execution will deliver greater long–term value for our customers and investors," Hili concluded.

The General Crop Protection (CP) Market Environment

Through 2025, channel inventory returned to pre-pandemic levels in most countries, following crop protection demand recovery. Pricing pressures remain high, driven by production over-capacity of active ingredients (AI). Crop commodity prices remain stably low, while farmer profitability remains tight leading to just-in-time purchasing patterns.¹

ADAMA's Strategy Execution

In early 2024, ADAMA launched its Fight Forward transformation plan to strengthen the company's foundations and improve profit and cash performance. The plan sharpened ADAMA's focus on priority countries and products, enhanced cost competitiveness, and established a more agile and streamlined operating model. These actions contributed to meaningful improvements in the company's financial metrics and operational discipline.

Building on Fight Forward's foundation, in 2026 ADAMA continues to advance its strategy, with a focus on enhancing its commercial capabilities to better serve customers, developing its differentiated portfolio and innovation pipeline, supporting a reliable and competitive supply of essential products, and pursuing a more efficient and responsive global manufacturing and supply network.

Sustainability

In 2025, ADAMA achieved higher ESG ratings across multiple agencies, including EcoVadis, GreenEye in Israel and Wind ESG Rating in China, reflecting the continued strengthening of the Company's ESG practices and the growing integration of sustainability considerations across its operations.

Portfolio Development Update

During 2025 ADAMA continued to register and launch multiple new products in markets across the globe, adding on to its differentiated product portfolio. The Company prioritized advanced, value-driven formulations and focused on new product introductions in segments where performance, reliability and cost competitiveness matter most. Alongside new launches, ADAMA maintained disciplined portfolio management to enhance overall product quality and relevance.

There were 139 new product launches in 2025². Several products were highlighted in the Company's earlier 2025 quarterly reports, and in Q4 2025 launches of differentiated products included:

• EDAPTIS^® (Italy) and PULIMAISI™(China): Two innovative post-emergence herbicides combining both Pinoxaden and Mesosulfuron-methyl to provide effective control of a broad spectrum of grasses, including resistant populations, with patented formulations that ensures stable and reliable performance.
• BELLALI^® (France): A robust, triazole-free fungicide combining Folpet and Azoxystrobin to deliver a dual mode of action, including a unique multi-site defense, designed to combat resistance and protect yields across wheat, barley and rye.
• COSAYR^® (France): A long-lasting Chlorantraniliprole-based suspension, to deliver fast and effective control of chewing insects across a wide range of horticultural and field crops.

Registrations of differentiated products during Q4 2025 included:

• BREVIS™, BREVIS™ SG, METAMITRON AI (Canada): A fruit thinner for managing flowering and fruiting in pome fruits such as apples and pears
• EDAPTIS^® (Ireland): This innovative post-emergence herbicide combines Pinoxaden and Mesosulfuron-methyl to provide effective control of a broad spectrum of grasses, including resistant populations, with a patented formulation that ensures stable and reliable performance.
• Registration of Prothioconazole based products, part of ADAMA's comprehensive portfolio of innovative solutions for cereal fungicides, including:
• AVASTEL^® in Hungary, Austria and Netherlands
• SORATEL^® in Estonia
• PORAFAM^® TITAN (Germany): A novel and unique herbicide combination for the control of broad-leaved weeds in winter oilseed rape, representing the first Aminopyralid based solution that ADAMA is registering in Europe.
• TELAVEX™ (Czech Republic): A powerful OD formulation for corn that combines Mesotrione and Thiencarbazone-methyl with a safener to deliver robust control of grass and broad-leaf weeds for both pre- and early post-emergence application.
• ATEKA™ (USA): A powerful Spirotetramat-based insecticide with full systemic action, designed to protect high-value crops from difficult to control sucking pests
• IZAVIA^® (India): A high-performance SC formulation combining Chlorantraniliprole and Emamectin Benzoate. This dual-action product delivers both rapid knockdown and long-lasting residual control against the toughest Lepidopteran pests
• DOMAGO^® (India): A formulation combining Penoxsulam, Pretilachlor and the safener Fenclorim offering an effective weed control while guaranteeing a high safety to rice.
• MASTERCOP^® 25 SC (Thailand): A broad-spectrum fungicide and bactericide based on copper sulfate pentahydrate, providing effective control of a wide range of fungal and bacterial diseases in range of crops including: berries, cucurbits, grapes, fruiting vegetables, pome fruits, potatoes, and tree nuts.
• CUTLASS^® (Australia): A powerful, selective herbicide for the control of difficult broadleaf weeds in cereals, maize, pasture and waste areas.
• HIGHCARD^® (Spain): Rice Cropping Solution for control of troublesome weeds, providing rotation flexibility and superior crop safety.

In addition, patents granted during Q4 2025 included a SORATEL™ formulation patent in the United States and Israel, and U.S. patents for Saflufenacil SL and the Fipronil & Imidacloprid mixture.

Geopolitical Situation

ADAMA is headquartered and has three manufacturing sites in Israel. Regional tensions escalated on October 7, 2023, and more recently widened on February 28, 2026. The Company's Israeli production sites and supply chain, including ports, continue to operate without significant delays. As of this publication date, the events have not had nor are expected to have material impact on the Company's ability to support its markets, its ongoing activities, or its consolidated financial results.

ADAMA is a global company with manufacturing and formulation facilities in several locations around the world, principally in Israel, China and Brazil. The Company's management appointed a dedicated task force to analyze implications of global tariff policies on ADAMA and its sector, and to closely monitor and manage the situation and the potential impact on ADAMA's global network. Despite the uncertainty regarding changes to trade and tariff policies around the world, the Company currently expects that the impact on its operations and business results will continue to be immaterial.

Financial Highlights

Revenues in the fourth quarter declined by approximately 8% (-9% in RMB; -10% in CER) compared to the fourth quarter of 2024 to $1,026 million, reflecting decreases of 8% in volumes and 2% in prices, partially offset by positive foreign exchange impacts. In the fourth quarter, lower volumes were recorded, mainly reflecting the Company's strategic decisions to pivot away from selling some basic chemical products as well as phasing and the channel's just-in-time purchasing patterns. Prices remained weak in most regions mainly due to low prices of active ingredients in light of overcapacity, as well as low commodity prices, which put pressure on farmers.

Revenues for the full year were $4,051 million, a decline of approximately 2% (-2% in RMB; -2% in CER) compared to the full year of 2024, reflecting a decrease of 2% in prices attributable to the reasons stated above. Volumes in the full year were stable as demand recovery due to inventory improvement in several regions was offset by the impacts of extreme weather conditions in some key countries, the Company's strategic decisions to optimize its portfolio and geographical presence and reduce selling some basic chemical products, and significant declines in Turkey in Q1.

Table 2. Regional Sales Performance

Full story available on Benzinga.com